FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways
Abstract
Mutations in the receptor tyrosine kinase gene fibroblast growth factor receptor 2 (FGFR2) occur at a high frequency in endometrial cancer (EC) and have been linked to advanced and recurrent disease. However, little is known about how these mutations drive carcinogenesis.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2023
- Source ID
- 10.1002/ctm2.1223
Entities
People
- Eric J Devor
- Erin B. Dickerson
- Garima Dixit
- Jesus Gonzalez‐bosquet
- Joseph Skurski
- Kimberly K Leslie
- Priya D. Issuree
- Thorsten Maretzky
- Warren B. Nothnick
Organizations
- American Cancer Society
- National Institutes of Health
- United States Department of Defense
- University of Iowa
- University of Kansas
- University of Minnesota
- University of New Mexico